



SAFETY DATA SHEET

Revision date: 03-Oct-2014

Version: 5.0

Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: PF-05212366 (Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein [rLP2086; subfamily A and B; E coli] Vaccine)

Trade Name: TRUMENBA
Compound Number: PF-05212366
Synonyms: PF-05212366 (Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein [rLP2086; subfamily A and B; E coli] Vaccine); rLP2086; MnBvLP2086
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Vaccine

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Other Hazards No data available
Australian Hazard Classification (NOHSC): Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

SAFETY DATA SHEET

Material Name: PF-05212366 (Neisseria meningitidis
Serogroup B Bivalent Recombinant Lipoprotein [rLP2086;
subfamily A and B; E coli] Vaccine)
Revision date: 03-Oct-2014

Page 2 of 7

Version: 5.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Polysorbate 80	9005-65-6	Not Listed	Not Listed	Not Listed	*
L-Histidine	71-00-1	200-745-3	Not Listed	Not Listed	*
MnBrLP2086	Proprietary	Not Listed	Not Listed	Not Listed	*
SODIUM CHLORIDE	7647-14-5	231-598-3	Not Listed	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: No data available

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

SAFETY DATA SHEET

Material Name: PF-05212366 (Neisseria meningitidis
Serogroup B Bivalent Recombinant Lipoprotein [rLP2086;
subfamily A and B; E coli] Vaccine)
Revision date: 03-Oct-2014

Page 3 of 7

Version: 5.0

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Restrict access to work area. Avoid open handling. Minimize generating airborne mists and vapors. Use process containment, local exhaust ventilation or perform work under fume hood/fume cupboard. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames.

Specific end use(s): Vaccine

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

L-Histidine

Latvia OEL - TWA 5 mg/m³

SODIUM CHLORIDE

Latvia OEL - TWA 5 mg/m³

Lithuania OEL - TWA 5 mg/m³

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures.
Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Wear impervious gloves if skin contact is possible.

Eyes: Wear safety glasses as minimum protection.

Skin: Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

SAFETY DATA SHEET

Material Name: PF-05212366 (Neisseria meningitidis
Serogroup B Bivalent Recombinant Lipoprotein [rLP2086;
subfamily A and B; E coli] Vaccine)
Revision date: 03-Oct-2014

Page 4 of 7

Version: 5.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid	Color:	Clear
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	6.5 - 8.5
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	

MnBrLP2086

No data available

L-Histidine

No data available

SODIUM CHLORIDE

No data available

Polysorbate 80

No data available

Decomposition Temperature (°C):	No data available.
--	--------------------

Evaporation Rate (Gram/s):	No data available
Vapor Pressure (kPa):	No data available
Vapor Density (g/ml):	No data available
Relative Density:	No data available
Viscosity:	No data available

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: Toxicological properties of the formulation have not been fully investigated. The information included in this section describes the potential hazards of the individual ingredients.

SAFETY DATA SHEET

Material Name: PF-05212366 (Neisseria meningitidis
Serogroup B Bivalent Recombinant Lipoprotein [rLP2086;
subfamily A and B; E coli] Vaccine)
Revision date: 03-Oct-2014

Page 5 of 7

Version: 5.0

11. TOXICOLOGICAL INFORMATION

Short Term: In the event of accidental injection, an allergic reaction may occur. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted.

Known Clinical Effects: Based on clinical trials in humans, possible adverse effects following exposure to this compound may include:

Acute Toxicity: (Species, Route, End Point, Dose)

L-Histidine

Rat Oral LD 50 > 15 g/kg
Rat Para-periosteal LD 50 > 2g/kg
Mouse Oral LD 50 > 15g/kg
Mouse Intravenous LD 50 > 2g/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³
Rat Oral LD 50 3g/kg
Mouse Oral LD 50 4g/kg
Rabbit Dermal LD 50 > 10g/kg

Polysorbate 80

Rat Intravenous LD 50 1790 mg/kg
Mouse Oral LD 50 25g/kg

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin Irritation Rabbit Mild
Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

MnBrLP2086

9 Week(s) Rabbit Intramuscular 400 ug/dose/2weeks NOEL None identified

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

MnBrLP2086

Fertility and Embryonic Development Rabbit Intramuscular * 200 ug/dose NOEL Reproductive toxicity, Developmental toxicity

Reproductive & Development

Toxicity Comments: MnBrLP2086: * NOTE: 4 doses -17 and 4 days prior to mating, gestation days 10 and 24.

Carcinogen Status:

Not listed as a carcinogen by IARC, NTP or US OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated.

SAFETY DATA SHEET

Material Name: PF-05212366 (Neisseria meningitidis
Serogroup B Bivalent Recombinant Lipoprotein [rLP2086;
subfamily A and B; E coli] Vaccine)
Revision date: 03-Oct-2014

Page 6 of 7

Version: 5.0

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transportation as per defining criteria in the international transportation regulations and the shipper's knowledge of the material.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Additional Information: This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

Polysorbate 80

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

SAFETY DATA SHEET

Material Name: PF-05212366 (Neisseria meningitidis
Serogroup B Bivalent Recombinant Lipoprotein [rLP2086;
subfamily A and B; E coli] Vaccine)
Revision date: 03-Oct-2014

Page 7 of 7

Version: 5.0

15. REGULATORY INFORMATION

L-Histidine

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-745-3

MnBrLP2086

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

SODIUM CHLORIDE

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-598-3

16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 2 - Hazard Identification. Updated Section 11 - Toxicology Information.

Revision date: 03-Oct-2014
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet